MWNA
MOLN

Marshall Wace North America’s Molecular Partners MOLN Stock Holding History

Marshall Wace North America’s Portfolio MOLN Stock Details MOLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-96,499
Closed -$1.97M – 1609
2021
Q2 		$1.97M Buy
+96,499
New +$1.91M 0.01% 812

Other funds holding MOLN

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
CCM
CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $59.6M AUM 181.61% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.04B AUM 31.03% 1-Year Est. Return

Marshall Wace North America's MOLN Position: Q3 2021 in Review

Marshall Wace North America sold out of Molecular Partners (MOLN) in Q3 2021, closing a stake of 96,499 shares — an estimated $1.97M sold.

Marshall Wace North America first reported a position in MOLN in Q2 2021 and held it in 1 quarter. The position peaked at $1.97M in Q2 2021. 9 funds tracked by Wall St. Rank hold MOLN as of Q3 2021.

  • Marshall Wace North America reported no remaining Molecular Partners position as of Q3 2021 after selling out during the quarter.
  • Marshall Wace North America sold 96,499 Molecular Partners shares in Q3 2021, an estimated $1.97M.
  • Marshall Wace North America first reported a position in Molecular Partners in Q2 2021 and held it in 1 quarter.
  • Marshall Wace North America's Molecular Partners position peaked at $1.97M in Q2 2021.
  • 9 funds tracked by Wall St. Rank held Molecular Partners as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.